中生北控生物科技(08247)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

08247 中生北控生物科技

未开盘 09-21 15:08:10

3.185

+0.000

0.00%

最高3.250	最低3.080	成交量1.00万
今开3.250	昨收3.185	日振幅5.34%
总市值4.61亿	流通市值2.05亿	总股本1.45亿
成交额3.18万	换手率0.02%	流通股本6,429万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"08247","market":"HK","secType":"STK","nameCN":"中生北控生物科技","latestPrice":3.185,"timestamp":1789974490699,"preClose":3.185,"halted":0,"volume":10000,"delay":0,"changeRate":0,"floatShares":64286143,"shares":144707176,"eps":-0.41378299755225,"marketStatus":"未开盘","change":0,"latestTime":"09-21 15:08:10","open":3.25,"high":3.25,"low":3.08,"amount":31830,"amplitude":0.053375,"askPrice":3.185,"askSize":28000,"bidPrice":2.99,"bidSize":2000,"shortable":0,"etf":0,"ttmEps":-0.3439404130107324,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790040600000},"marketStatusCode":0,"adr":0,"listingDate":1140969600000,"exchange":"SEHK","adjPreClose":3.185,"openAndCloseTimeList":[[1789954200000,1789963200000],[1789966800000,1789977600000]],"volumeRatio":0.2777777780092593,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/08247","defaultTab":"news","newsList":[{"id":"1182141823","title":"中生北控生物科技（08247）主要交易通函寄发时间延期至2026年10月30日","url":"https://stock-news.laohu8.com/highlight/detail?id=1182141823","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182141823?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:36","pubTimestamp":1788510967,"startTime":"0","endTime":"0","summary":"中生北控生物科技股份有限公司9月4日公告称，因需要额外时间编制及落实拟载入通函的资料，原定于2026年9月4日或之前向股东寄发的有关收购及认购上海匠簇合共70.3%股权的主要交易通函，现预期将延期至2026年10月30日或之前寄发。公告显示，本次延迟不影响交易条款及其他安排。中生北控生物科技表示，相关通函将自刊登日起至少七日内登载于香港交易所网站及公司官网。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183790071","title":"中生北控生物科技更新8月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1183790071","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183790071?lang=zh_cn&edition=full","pubTime":"2026-09-01 14:16","pubTimestamp":1788243387,"startTime":"0","endTime":"0","summary":"2026年9月1日，中生北控生物科技（股票代码：08247）公布2026年8月股份变动月报表。公告显示，截至2026年8月31日，公司法定及注册股本分别保持在人民币144,707,176元，包含H股64,286,143股与内资股80,421,033股，较上月底无增减变化。\n本月期间，公司未有新增发行股份、购回股份、注销或库藏股变动。同时，未披露任何股份期权计划、可换股债券或其他股权激励安排的变动信息。公司确认已满足香港联合交易所有限公司GEM上市规则对公众持股量的要求。\n公告由公司秘书董渙樟签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660275282","title":"中生北控生物科技(08247.HK)发布中期业绩 归母净亏损833.1万元 同比收窄53.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660275282","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660275282?lang=zh_cn&edition=full","pubTime":"2026-08-20 21:01","pubTimestamp":1787230906,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["08247","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168543012","title":"中生北控生物科技（08247）发布2026年中期业绩：营收8.31亿元 归母亏损大幅收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1168543012","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168543012?lang=zh_cn&edition=full","pubTime":"2026-08-20 20:56","pubTimestamp":1787230588,"startTime":"0","endTime":"0","summary":"中生北控生物科技股份有限公司于2026年8月20日披露截至2026年6月30日止六个月未审计中期业绩。报告期内，本集团实现营业收入人民币83,132千元，同比减少14.13%。受营业收入下降影响，期内营业成本为49,930千元，同比减少14.58%；毛利33,202千元，较同期38,360千元下降13.46%，毛利率为39.9%，与同期39.6%基本持平。受费用压缩影响，营业亏损由同期的22,920千元收窄至13,046千元。基本及摊薄每股亏损均为0.06元，较同期的0.12元明显改善。董事会建议不派发2026年中期股息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198139850","title":"中生北控生物科技（08247）将于8月20日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1198139850","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198139850?lang=zh_cn&edition=full","pubTime":"2026-08-10 16:41","pubTimestamp":1786351276,"startTime":"0","endTime":"0","summary":"中生北控生物科技股份有限公司8月10日公告称，公司董事会已发出会议通知，董事会会议拟于2026年8月20日（星期四）召开。董事会将就以下事项进行审议：","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657164216","title":"溢价405%收购上海匠簇70.3%股权 中生北控的“IVD全链条”赌局","url":"https://stock-news.laohu8.com/highlight/detail?id=2657164216","media":"新浪证券","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657164216?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:54","pubTimestamp":1786092840,"startTime":"0","endTime":"0","summary":"交易完成后，上海匠簇将成为中生北控的非全资附属公司，财务业绩并入集团合并报表。据公告披露，上海匠簇2025年经审计净利润为1.105亿元。以1.64亿元收购70.3%股权推算，标的整体估值约2.33亿元，对应2025年净利润的市盈率约为2.1倍。上海匠簇的“无形资产”确实存在。中生北控2025年营收仅1.84亿元，归母净利润亏损5114.2万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-08-07/doc-inimnrar4838631.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","08247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657503679","title":"中生北控生物科技拟1.64亿元取得上海匠簇约70.3%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2657503679","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657503679?lang=zh_cn&edition=full","pubTime":"2026-08-06 09:55","pubTimestamp":1785981300,"startTime":"0","endTime":"0","summary":"8月5日，中生北控生物科技（08247）发布公告，公司作为投资方，将通过股权收购及增资方式取得上海匠簇有限公司约70.3%股权，上海匠簇将成为公司的非全资附属公司，纳入公司综合财务报表。本次交易的代价总额为1.64亿元。具体来看，公司向潘震河收购上海匠簇10%股权，交易金额为770万元。公司将根据一般授权，按每股3.2港元的发行价向潘震河发行279万股H股，以支付交易代价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608063833577240.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608063833577240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["08247","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188059777","title":"中生北控生物科技拟收购上海江慈70.3%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1188059777","media":"投资观察","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188059777?lang=zh_cn&edition=full","pubTime":"2026-08-05 23:23","pubTimestamp":1785943420,"startTime":"0","endTime":"0","summary":"8月5日，中生北控生物科技（股票代码：08247.HK）宣布，计划收购上海江慈70.3%的股权。\n根据公告，该公司将分两步完成交易。首先，以280万股H股作为支付对价，每股作价3.2港元，此部分对应上海江慈10%的股权，价值约770万元人民币。接着，再通过现金出资1.563亿元人民币，认购上海江慈67%的股权。\n整个交易的总对价约为1.64亿元人民币，折合港元约1.903亿。完成收购后，公司将持有上海江慈70.3%的股权。\n具体交易细节与后续进展，请继续关注公司公告。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","08247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657256375","title":"中生北控生物科技(08247.HK)拟约1.64亿元获取上海匠簇70.3%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2657256375","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657256375?lang=zh_cn&edition=full","pubTime":"2026-08-05 23:06","pubTimestamp":1785942364,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["08247","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142957298","title":"中生北控生物科技（08247）拟斥资约1.64亿元收购并增资上海匠簇 持股升至70.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1142957298","media":"公告速递","labels":["shareholding","merge","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142957298?lang=zh_cn&edition=full","pubTime":"2026-08-05 23:00","pubTimestamp":1785942057,"startTime":"0","endTime":"0","summary":"2026年8月5日，中生北控生物科技公告，与上海匠簇科技有限公司及其原股东签署《增资与合作协议》，公司将通过两步交易合计取得上海匠簇经增资后约70.3%股权。第二步，公司以现金人民币156,333,300元认购上海匠簇新增注册资本，取得其增资后67%股权。两步交易总代价人民币164,033,300元；交易完成后，公司合计持有上海匠簇约70.3%股权，丙方持股约29.7%，上海匠簇将成为公司非全资附属公司，其财务业绩将并入集团报表。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111519271","title":"中生北控生物科技7月股份变动月报表发布，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1111519271","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111519271?lang=zh_cn&edition=full","pubTime":"2026-08-03 15:25","pubTimestamp":1785741935,"startTime":"0","endTime":"0","summary":"2026年8月3日，中生北控生物科技股份有限公司公布了2026年7月股份变动月报表。公告显示，截至2026年7月31日，公司的已发行股份及注册股本保持稳定，未发生新增发行、购回、注销或库藏股变动。根据月报信息，普通股包括H股与内资股两类。至本月末，公司法定/注册股本合计人民币144,707,176元，与上月底相同；H股合计64,286,143股、内资股合计80,421,033股两项数据均未出现变动。公司同时确认，H股满足相关公众持股量要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159603241","title":"中生北控生物科技(08247)主席陈鹏增持430.02万股 内资股持股比例升至19.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=1159603241","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159603241?lang=zh_cn&edition=full","pubTime":"2026-07-16 18:45","pubTimestamp":1784198728,"startTime":"0","endTime":"0","summary":"中生北控生物科技股份有限公司7月16日公告称，公司主席、总裁、执行董事及主要股东陈鹏于2026年6月15日至2026年7月14日期间，通过景宁国科康仪企业管理中心及国科健康院创新研究院（合肥）合伙企业，以总代价约人民币10.53百万元，场外合共购入4,300,176股公司内资股，收购价格介乎每股人民币2.40元至人民币2.50元，该笔增持占公司已发行股份总数的2.97%。公司表示，将持续关注陈鹏的持股变化并按规定履行信息披露义务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175258582","title":"中生北控生物科技收购案总对价1.053亿元 每股作价介于2.40至2.50元","url":"https://stock-news.laohu8.com/highlight/detail?id=1175258582","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175258582?lang=zh_cn&edition=full","pubTime":"2026-07-16 18:42","pubTimestamp":1784198524,"startTime":"0","endTime":"0","summary":"中生北控生物科技公司一项收购交易的总对价确定为人民币1.053亿元，每股收购价格区间设定在人民币2.40元至2.50元之间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","08247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651445260","title":"中生北控生物科技(08247.HK)获主要股东陈鹏增持约430.02万股公司内资股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651445260","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651445260?lang=zh_cn&edition=full","pubTime":"2026-07-16 18:42","pubTimestamp":1784198523,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["08247","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195224305","title":"中生北控生物科技、元臻投资及自然人终止一致行动协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1195224305","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195224305?lang=zh_cn&edition=full","pubTime":"2026-07-03 18:53","pubTimestamp":1783076021,"startTime":"0","endTime":"0","summary":"中生北控生物科技股份有限公司、元臻投资及一位自然人已共同决定，终止就中生金域相关事项所达成的一致行动协议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08247","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125049139","title":"中生北控生物科技6月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1125049139","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125049139?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:23","pubTimestamp":1782984185,"startTime":"0","endTime":"0","summary":"中生北控生物科技股份有限公司于2026年7月2日发布2026年6月股份变动月报表。根据公告显示，公司法定/注册股本合计为人民币144,707,176元，分为64,286,143股H股及80,421,033股内资股，全部股本面值为每股人民币1元。报告期内，公司已发行股份数与股本总额均保持不变，未发生新增发行、购回及注销或库藏股变动。截至2026年6月30日，该公司H股发行总数为64,286,143股，内资股发行总数为80,421,033股，均与上个月保持一致，库存股份数目为零，股本仍维持稳定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647302205","title":"中生北控生物科技(08247.HK)将采用中国企业会计准则编制财务会计报告 终止委任香港立信德豪为国际核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=2647302205","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647302205?lang=zh_cn&edition=full","pubTime":"2026-06-30 19:09","pubTimestamp":1782817756,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","08247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647530769","title":"中生北控生物科技：国际核数师辞任","url":"https://stock-news.laohu8.com/highlight/detail?id=2647530769","media":"南方财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647530769?lang=zh_cn&edition=full","pubTime":"2026-06-30 19:05","pubTimestamp":1782817500,"startTime":"0","endTime":"0","summary":"南财智讯6月30日电，中生北控生物科技（08247.HK）公告，香港立信德豪会计师事务所有限公司已辞任公司国际核数师，自2026年6月25日起生效。此次辞任系因公司董事会于2026年6月25日批准自2026年中期业绩及中期财务报告起采用中国企业会计准则编制财务会计报告，不再需要国际核数师服务。立信会计师事务所（特殊普通合伙）将继续担任公司中国核数师。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606303788502830.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606303788502830.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["08247","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191203043","title":"中生北控生物科技5月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1191203043","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191203043?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:21","pubTimestamp":1780305685,"startTime":"0","endTime":"0","summary":"中生北控生物科技股份有限公司于2026年6月1日发布5月股份变动月报表，报告期截至2026年5月31日。该公司成立于中华人民共和国，为股份有限公司。根据公告，截至5月31日，公司法定/注册股本总额约为人民币1.45亿元，相应股本结构保持不变。上述数据显示当月公司股本结构无变化，发行股份数目维持稳定。公告显示，公司已符合香港联交所GEM上市规则要求的公众持股量标准。该月报表由公司秘书董渙樟签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188943509","title":"中生北控生物科技4月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1188943509","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188943509?lang=zh_cn&edition=full","pubTime":"2026-05-04 16:47","pubTimestamp":1777884435,"startTime":"0","endTime":"0","summary":"中生北控生物科技股份有限公司（股票代码：08247）于2026年5月4日发布2026年4月股份变动月报表，报告期内公司股本总数稳定，未发生新增发行、购回、注销或库藏股变动。\n公司披露，截至4月30日，公司注册股本总额144,707,176股，其中包括H股64,286,143股，以及内资股80,421,033股，两类股份数量均与上月底保持一致。公司同时确认当月无任何股份期权、可换股票据或其他形式的已发行股份变动。\n报告显示，4月底公司已发行股份及公眾持股量符合香港联交所相关要求。此外，公告由公司秘书董渙樟签署，确认遵守香港联交所《上市规则》及相关法律法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08247"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zhongsheng.com.cn","stockEarnings":[{"period":"1week","weight":-0.0078},{"period":"1month","weight":-0.0109},{"period":"3month","weight":0.1136},{"period":"6month","weight":-0.1322},{"period":"1year","weight":2.3177},{"period":"ytd","weight":0.4093}],"compareEarnings":[{"period":"1week","weight":0.005},{"period":"1month","weight":-0.0372},{"period":"3month","weight":0.0731},{"period":"6month","weight":-0.0116},{"period":"1year","weight":-0.0566},{"period":"ytd","weight":-0.0229}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中生北控生物科技股份有限公司是一家主要从事研发、生产、销售及分销体外诊断试剂的中国公司。该公司的主要产品包括临床化学、免疫诊断产品、分子诊断产品、血液诊断产品、医学临床营养诊断产品及相关分析仪器及原料。该公司的产品主要用于肝功能、血脂、肾功能、心肌、特殊蛋白、微量元素、糖代谢等诊断。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.043754},{"month":2,"riseRate":0.444444,"avgChangeRate":0.04506},{"month":3,"riseRate":0.578947,"avgChangeRate":0.033322},{"month":4,"riseRate":0.35,"avgChangeRate":-0.004864},{"month":5,"riseRate":0.45,"avgChangeRate":0.040423},{"month":6,"riseRate":0.25,"avgChangeRate":-0.054052},{"month":7,"riseRate":0.4,"avgChangeRate":-0.040008},{"month":8,"riseRate":0.5,"avgChangeRate":0.05152},{"month":9,"riseRate":0.421053,"avgChangeRate":0.004554},{"month":10,"riseRate":0.368421,"avgChangeRate":0.002429},{"month":11,"riseRate":0.526316,"avgChangeRate":0.066742},{"month":12,"riseRate":0.421053,"avgChangeRate":0.016056}],"exchange":"SEHK","name":"中生北控生物科技","nameEN":"BIOSINO BIO-TEC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中生北控生物科技(08247)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中生北控生物科技(08247)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中生北控生物科技,08247,中生北控生物科技股票,中生北控生物科技股票老虎,中生北控生物科技股票老虎国际,中生北控生物科技行情,中生北控生物科技股票行情,中生北控生物科技股价,中生北控生物科技股市,中生北控生物科技股票价格,中生北控生物科技股票交易,中生北控生物科技股票购买,中生北控生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中生北控生物科技(08247)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中生北控生物科技(08247)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}